SAN.PA - Sanofi

Paris - Paris Delayed Price. Currency in EUR
73.30
+0.64 (+0.88%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close72.66
Open72.73
Bid0.00 x 0
Ask0.00 x 0
Day's Range72.70 - 73.55
52 Week Range62.88 - 86.39
Volume2,172,549
Avg. Volume2,665,308
Market Cap90.869B
Beta0.78
PE Ratio (TTM)24.69
EPS (TTM)2.97
Earnings DateOct 31, 2018
Forward Dividend & Yield3.03 (4.18%)
Ex-Dividend Date2018-05-11
1y Target Est79.80
  • CNBCyesterday

    'Ambien tweeting' is becoming a popular excuse — because it actually can cause bizarre side effects

    Elon Musk shocked investors last week when he tweeted he was considering taking Tesla private at $420 a share and that funding was secured. Earlier this year, Roseanne Barr blamed Ambien for her sending a tweet comparing former Obama aide Valerie Jarrett to an ape. Tesla TSLA CEO Elon Musk told The New York Times he sometimes takes Ambien because it's "often a choice of no sleep or Ambien." But some concerned board members have noted that the drug contributes to Musk's late-night tweeting, the outlet reported, citing a person familiar with the board's thinking.

  • Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018
    Market Realist5 days ago

    Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018

    GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines. The segment’s revenue grew 13% YoY (year-over-year) to ~1.3 billion British pounds in Q2 2018, as a result of 16% operating revenue growth and a 3% impact by foreign exchange. The chart below shows the segment’s revenue since the first quarter of 2017.

  • Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
    Market Realist5 days ago

    Novo Nordisk’s Fast-Acting Insulins: A Performance Overview

    In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.

  • How GlaxoSmithKline’s Segments Have Performed
    Market Realist5 days ago

    How GlaxoSmithKline’s Segments Have Performed

    As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...

  • Analyzing GlaxoSmithKline’s Revenue Trends
    Market Realist5 days ago

    Analyzing GlaxoSmithKline’s Revenue Trends

    In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.

  • GlobeNewswire5 days ago

    Sanofi: Disclosure of trading in own shares

    Reporting EN This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for ...

  • Novo Nordisk: A Financial Overview after the First Half of 2018
    Market Realist5 days ago

    Novo Nordisk: A Financial Overview after the First Half of 2018

    Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.

  • Reuters6 days ago

    Amicus sets $315,000 price for new Fabry disease treatment

    Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States. Galafold - approved on Friday by U.S. regulators - is the first new Fabry disease treatment in the country in over 15 years, and will compete with Sanofi SA's infused Fabrazyme, which has an average U.S. list price of $340,000 for adults, according to Amicus. Galafold is an oral therapy for Fabry disease, a sometimes fatal genetic condition in which accumulation of fat damages several organs.

  • Reuters8 days ago

    Amicus Therapeutics receives U.S. approval for Fabry disease drug

    U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs. Galafold, known chemically as migalastat, will be the first new Fabry treatment on the U.S. market in over 15 years, and will compete with Sanofi SA’s infused Fabrazyme. An estimated 3,000 people in the United States are diagnosed with the disease.

  • In $270M Peninsula vaccine company buyout, small players look to be big shots
    American City Business Journals9 days ago

    In $270M Peninsula vaccine company buyout, small players look to be big shots

    A deal with its roots in January's J.P. Morgan Healthcare Conference adds power to a small vaccine maker's quest to go after specialty vaccines amid a consolidating industry.

  • What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates
    Market Realist9 days ago

    What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates

    Alnylam Pharmaceuticals’ (ALNY) interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

  • Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
    Market Realist9 days ago

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.

  • Reuters10 days ago

    Factbox: European companies respond to latest Iran sanctions

    New U.S. sanctions against Iran took effect on Tuesday and President Donald Trump, who defied Washington's allies to impose them, pledged that companies doing business with Tehran would be barred from ...

  • Emergent BioSolutions Makes Up for Last Quarter
    Motley Fool11 days ago

    Emergent BioSolutions Makes Up for Last Quarter

    Timing issues in the first quarter are a thing of the past.

  • Reuters12 days ago

    Factbox: European companies respond to latest Iran sanctions

    German car and truck manufacturer Daimler has dropped plans to expand its Iran business. "We have ceased our already restricted activities in Iran in accordance with the applicable sanctions", Daimler said. In early 2016, Daimler established a joint venture with vehicle manufacturer and dealer Iran Khodro Co to make and distribute Mercedes-Benz trucks in the country.

  • The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis
    Zacks13 days ago

    The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis

    The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis

  • Regeneron Stock Up 7% on Strong Q2 2018 Results
    Market Realist16 days ago

    Regeneron Stock Up 7% on Strong Q2 2018 Results

    On August 2, Regeneron Pharmaceuticals (REGN) posted earnings results for its fiscal second quarter of 2018, which ended on June 30. It posted strong results and raised its fiscal 2018 guidance. It registered strong sales and earnings while achieving significant product pipeline milestones.

  • Eli Lilly’s Q2 2018 Earnings: New Products
    Market Realist16 days ago

    Eli Lilly’s Q2 2018 Earnings: New Products

    Eli Lilly & Co.’s (LLY) new products portfolio includes several drugs that have been launched since 2014. This portfolio includes Olumiant, Lartruvo, Taltz, Jardiance, Trulicity, Cyramza, Basaglar, and Verzenio. The chart below compares the revenues for LLY’s new products since the first quarter of 2017.

  • The Wall Street Journal16 days ago

    [$$] European Corporate Roundup for Wednesday

    It’s another busy day for European corporate news, with forecast-beating numbers from Air France-KLM, BNP Paribas and Lloyds Banking the highlights of a fresh batch of company earnings.

  • Investor's Business Daily16 days ago

    Can Regeneron Stock Hit $400 For The First Time This Year?

    Regeneron Pharmaceuticals on Thursday reported adjusted income of $5.45 per share on $1.61 billion in sales for the second quarter.

  • Regeneron (REGN) Q2 Earnings Beat on Strong Dupixent Sales
    Zacks16 days ago

    Regeneron (REGN) Q2 Earnings Beat on Strong Dupixent Sales

    Regeneron (REGN) reports impressive Q2 results on the back of growth in both Eylea and Dupixent sales.

  • More drugmakers build Brexit stockpiles as EU agency faces exodus
    Reuters17 days ago

    More drugmakers build Brexit stockpiles as EU agency faces exodus

    PARIS/ZURICH/LONDON (Reuters) - Sanofi and Novartis said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal. At the same time the European Medicines Agency, which oversees drug safety across the bloc, warned of bigger than expected staff losses and cuts in some activities as a result of having to move from London to Amsterdam due to Brexit. Europe's equivalent of the U.S. Food and Drug Administration now expects to lose around 30 percent of its workforce as it prepares to relocate by March 2019.

  • More drugmakers build Brexit stockpiles as EU agency faces exodus
    Reuters17 days ago

    More drugmakers build Brexit stockpiles as EU agency faces exodus

    PARIS/ZURICH/LONDON (Reuters) - Sanofi (SASY.PA) and Novartis (NOVN.S) said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal. At the same time the European Medicines Agency, which oversees drug safety across the bloc, warned of bigger than expected staff losses and cuts in some activities as a result of having to move from London to Amsterdam due to Brexit. Europe's equivalent of the U.S. Food and Drug Administration now expects to lose around 30 percent of its workforce as it prepares to relocate by March 2019.

  • Associated Press18 days ago

    Drugmaker stockpiling more medicines in UK ahead of Brexit

    LONDON (AP) — Pharmaceutical company Sanofi has begun to stockpile more drugs in Britain than usual as part of contingency plans for delays in deliveries after Britain leaves the European Union.

  • The Wall Street Journal18 days ago

    [$$] Sanofi Has Been Stockpiling Drugs for No-Deal Brexit for Six Months

    SA has been making drug-shortage contingency plans for more than a year to prepare for the U.K. failing to reach a deal with the European Union on Brexit, according to a person familiar with the matter. The move is the latest sign large European companies are worried about the prospects of a hard Brexit, where the U.K. doesn’t reach a deal over its future relationship with the European Union, despite repeated attempts at reassurance from British government officials.